Drugs / HA131
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07282509 | Dec 2025 → Jun 2028 expected | hepatocellular carcinoma | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HA131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07282509 ↗ |
| Route | Other | “Transcatheter Arterial Infusion.” NCT07282509 ↗ |